We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Turn for the worse

30 October 2013 By Robert Cyran, Neil Unmack

The world’s largest generic drugmaker has lost boss Jeremy Levin. That raises governance concerns and casts doubt on the firm’s ability to weather the expiration of patents on its biggest seller. A takeover could be in the offing, but shareholders probably won’t be so lucky.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)